Literature DB >> 22787206

The NS1 protein of influenza A virus blocks RIG-I-mediated activation of the noncanonical NF-κB pathway and p52/RelB-dependent gene expression in lung epithelial cells.

Andrea Rückle1, Emanuel Haasbach, Ilkka Julkunen, Oliver Planz, Christina Ehrhardt, Stephan Ludwig.   

Abstract

Influenza A virus (IAV) infection of epithelial cells activates NF-κB transcription factors via the canonical NF-κB signaling pathway, which modulates both the antiviral immune response and viral replication. Since almost nothing is known so far about a function of noncanonical NF-κB signaling after IAV infection, we tested infected cells for activation of p52 and RelB. We show that the viral NS1 protein strongly inhibits RIG-I-mediated noncanonical NF-κB activation and expression of the noncanonical target gene CCL19.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787206      PMCID: PMC3446553          DOI: 10.1128/JVI.00323-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.

Authors:  U Senftleben; Y Cao; G Xiao; F R Greten; G Krähn; G Bonizzi; Y Chen; Y Hu; A Fong; S C Sun; M Karin
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  NF-kappaB signaling differentially regulates influenza virus RNA synthesis.

Authors:  Naveen Kumar; Zhong-Tao Xin; Yuhong Liang; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

5.  NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

Review 6.  Structure, regulation and function of NF-kappa B.

Authors:  U Siebenlist; G Franzoso; K Brown
Journal:  Annu Rev Cell Biol       Date:  1994

7.  Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation.

Authors:  Gutian Xiao; Abraham Fong; Shao-Cong Sun
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

8.  Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome.

Authors:  Mirco Schmolke; Dorothee Viemann; Johannes Roth; Stephan Ludwig
Journal:  J Immunol       Date:  2009-09-28       Impact factor: 5.422

Review 9.  Influenza viruses and the NF-kappaB signaling pathway - towards a novel concept of antiviral therapy.

Authors:  Stephan Ludwig; Oliver Planz
Journal:  Biol Chem       Date:  2008-10       Impact factor: 3.915

10.  Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression.

Authors:  Eva-K Pauli; Mirco Schmolke; Thorsten Wolff; Dorothee Viemann; Johannes Roth; Johannes G Bode; Stephan Ludwig
Journal:  PLoS Pathog       Date:  2008-11-07       Impact factor: 6.823

View more
  28 in total

1.  The non-canonical NF-κB pathway is induced by cytokines in pancreatic beta cells and contributes to cell death and proinflammatory responses in vitro.

Authors:  Kira Meyerovich; Makiko Fukaya; Leticia F Terra; Fernanda Ortis; Decio L Eizirik; Alessandra K Cardozo
Journal:  Diabetologia       Date:  2015-12-03       Impact factor: 10.122

2.  Noncanonical NF-κB pathway controls the production of type I interferons in antiviral innate immunity.

Authors:  Jin Jin; Hongbo Hu; Haiyan S Li; Jiayi Yu; Yichuan Xiao; George C Brittain; Qiang Zou; Xuhong Cheng; Frédérick A Mallette; Stephanie S Watowich; Shao-Cong Sun
Journal:  Immunity       Date:  2014-03-20       Impact factor: 31.745

3.  Schlafen 14 (SLFN14) is a novel antiviral factor involved in the control of viral replication.

Authors:  Rak-Kyun Seong; Seong-Wook Seo; Ji-Ae Kim; Sarah J Fletcher; Neil V Morgan; Mukesh Kumar; Young-Ki Choi; Ok Sarah Shin
Journal:  Immunobiology       Date:  2017-07-11       Impact factor: 3.144

4.  The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation.

Authors:  Chanan Meydan; Nimrod Madrer; Hermona Soreq
Journal:  Front Immunol       Date:  2020-10-09       Impact factor: 7.561

Review 5.  The non-canonical NF-κB pathway in immunity and inflammation.

Authors:  Shao-Cong Sun
Journal:  Nat Rev Immunol       Date:  2017-06-05       Impact factor: 53.106

Review 6.  Targeting signaling factors for degradation, an emerging mechanism for TRAF functions.

Authors:  Xiao-Dong Yang; Shao-Cong Sun
Journal:  Immunol Rev       Date:  2015-07       Impact factor: 12.988

7.  LncNSPL facilitates influenza A viral immune escape by restricting TRIM25-mediated K63-linked RIG-I ubiquitination.

Authors:  Jingjing Jiang; Yuyu Li; Zeyu Sun; Lan Gong; Xuehui Li; Fan Shi; Jian Yao; Yuting Meng; Xiaohua Meng; Qiong Zhang; Yuchong Wang; Xiaoling Su; Hongyan Diao
Journal:  iScience       Date:  2022-06-15

8.  Influenza A Virus NS1 Protein Binds as a Dimer to RNA-Free PABP1 but Not to the PABP1·Poly(A) RNA Complex.

Authors:  Cyrus M de Rozières; Simpson Joseph
Journal:  Biochemistry       Date:  2020-11-10       Impact factor: 3.162

9.  Downregulation of microRNA‑221 facilitates H1N1 influenza A virus replication through suppression of type‑IFN response by targeting the SOCS1/NF‑κB pathway.

Authors:  Nali Zhang; Yuan Ma; Yuheng Tian; Yafei Zhou; Yuhua Tang; Shaobo Hu
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

Review 10.  Evasion of influenza A viruses from innate and adaptive immune responses.

Authors:  Carolien E van de Sandt; Joost H C M Kreijtz; Guus F Rimmelzwaan
Journal:  Viruses       Date:  2012-09-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.